Advisor, guide-RNA Process Development jobs in United States
cer-icon
Apply on Employer Site
company-logo

Eli Lilly and Company · 8 hours ago

Advisor, guide-RNA Process Development

Eli Lilly and Company is a global healthcare leader dedicated to improving lives through innovative medicines. They are seeking an experienced process chemist to join the guide-RNA process development team, focusing on clinical manufacturing process development and supporting guide-RNA drug substance process development for clinical programs.

BiotechnologyHealth CareMedicalPharmaceutical
check
H1B Sponsor Likelynote

Responsibilities

Design and execute solid-phase synthesis and purification experiments to support process development and scale-up of oligonucleotide drug substance manufacturing
Lead guide-RNA process development efforts by identifying areas of continuous improvement through literature and state-of-art practices and applying these learnings to Verve’s gRNA process development projects
Collaborate cross-functionally with process and analytical teams to progress process and manufacturing technology development projects
Review and provide technical feedback on internal and external collaborators experimental designs and results
Participate actively in technical discussions and meetings, proactively communicate technical findings and results to stakeholders, train and support teammates as needed
Partner closely with members of facilities, lab operations, and safety to maintain the highest level of safety standards within the lab
Keep an updated lab notebook, order materials, maintain lab equipment, and support equipment troubleshooting as needed

Qualification

Oligonucleotide developmentSolid phase synthesisGuide-RNA synthesisGMP manufacturingChromatography (Akta)PrioritizeCommunication skillsInterpersonal skills

Required

PhD degree in a relevant scientific discipline with 1-2+ years of industry experience (synthesis, oligonucleotide development, solid phase synthesis, CMC) or MS degree with 6+ years of relevant industry experience (synthesis, oligonucleotide development, solid phase synthesis, CMC)
Experience designing and troubleshooting oligonucleotide solid phase synthesis studies. Strong preference for candidates who have experience with guide-RNA or longmer synthesis development backgrounds
Experience with oligonucleotide manufacturing processes and equipment including solid phase synthesis (Cytiva OligoSynt or OP100), cleavage and deprotection, chromatography (Akta), TFF, sterile filtration, single-use technology, and sterile/aseptic processing preferred
Background in oligonucleotide process development, scale-up, and GMP manufacturing
Strong communication skills (oral and written) and the ability to thrive in a team and goal driven environment

Preferred

Background in CRISPR guide RNA development strongly preferred
Use of strong interpersonal skills for collaboration
Ability to prioritize multiple activities and handle ambiguity

Benefits

Eligibility to participate in a company-sponsored 401(k)
Pension
Vacation benefits
Eligibility for medical, dental, vision and prescription drug benefits
Flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts)
Life insurance and death benefits
Certain time off and leave of absence benefits
Well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities)

Company

Eli Lilly and Company

company-logo
We're a medicine company turning science into healing to make life better for people around the world.

H1B Sponsorship

Eli Lilly and Company has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (514)
2024 (236)
2023 (167)
2022 (133)
2021 (57)
2020 (52)

Funding

Current Stage
Public Company
Total Funding
$6.5M
2024-02-12Post Ipo Debt· $6.5M
1978-01-13IPO

Leadership Team

leader-logo
David Ricks
Chair, CEO
linkedin
leader-logo
Lucas Montarce
Executive Vice President and Chief Financial Officer
linkedin
Company data provided by crunchbase